Abstract
In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Keywords: Colorectal cancer, metformin, prevention, treatment.
Current Drug Targets
Title:Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Volume: 17 Issue: 4
Author(s): Vladimir N. Anisimov
Affiliation:
Keywords: Colorectal cancer, metformin, prevention, treatment.
Abstract: In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Export Options
About this article
Cite this article as:
Anisimov N. Vladimir, Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data, Current Drug Targets 2016; 17 (4) . https://dx.doi.org/10.2174/1389450116666150309113305
DOI https://dx.doi.org/10.2174/1389450116666150309113305 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry The Signal Pathway of Antibiotic Alternatives on Intestinal Microbiota and Immune Function
Current Protein & Peptide Science Modulation of GSTP1-1 Oligomerization by Electrophilic Inflammatory Mediators and Reactive Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine A Meta-Analysis of Proteomic Blood Markers of Colorectal Cancer
Current Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery The Hedgehog Knows Many Tricks
Current Drug Targets QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism